InsiderTrades

Form 4 for TXG 10x Genomics, Inc.

Accepted 2022-02-17 00:00:00 ET · period of report 2022-02-15 · accession 0001567619-22-004884 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2022-02-17 2022-02-15 TXG CRUTCHFIELD BRADFORD Chief Commercial Off M - OptEx $1.16 +17.0K 114.7K +17% +$19.7K
D 2022-02-17 2022-02-15 TXG CRUTCHFIELD BRADFORD Chief Commercial Off S - Sale+OE $95.13 -17.0K 97.7K -15% -$1.62M
D 2022-02-17 2022-02-15 TXG CRUTCHFIELD BRADFORD Chief Commercial Off M - OptEx $0.00 -17.0K 392.0K -4% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Class A Common Stock 2022-02-15 M A 17,000 $1.16 114,653 D — —
2 Common Class A Common Stock 2022-02-15 S D 17,000 $95.13 97,653 D — — (F2) This transaction was executed in multiple trades at prices ranging from $95.00 to $95.38. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
3 Derivative Stock Option (right to buy) 2022-02-15 M D 17,000 $0.00 392,000 D $1.16 · — to 2027-02-03 17,000 Class A Common Stock (F3) This option, originally for 800,000 shares, of which 408,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.